For example, the inclusion of genetic markers, such as BRCA1 and BRCA2, may improve breast cancer risk prediction but may be unfeasible to deploy in population-wide screening programs due to costs, lab-related analysis burden, ethical concerns, and time delays. This evidence concerns the gene BRCA1 and breast cancer.